Clinical Trial

A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study aims to demonstrate that, in subjects with locally advanced or metastatic iodine - refractory differentiated thyroid cancer who have failed previous VEGFR - targeted therapy, AL2846 can significantly prolong progression - free survival (PFS) compared with placebo.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-02-28; most recent amendment 2025-12-24.
Status change: Not Yet Recruiting → Recruiting 2025-04-23
Trial Details
NCT Number NCT06860971
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Thyroid Cancer
Enrollment 144 participants
Start Date 2025-04-18
Primary Completion 2027-01 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-31